ESR1 and neoplasm: The PEPI score incorporates pathological tumor size, lymph node metastasis, estrogen receptor (ER) expression, and Ki67 expression level after presurgical endocrine therapy and has demonstrated its validity in estimating recurrence-free survival (RFS) in patients undergoing presurgical endocrine therapy.